Galmed Net Receivables from 2010 to 2026
| GLMD Stock | USD 0.61 0.06 8.96% |
Net Receivables | First Reported 2013-12-31 | Previous Quarter 433 K | Current Value 549 K | Quarterly Volatility 329.3 K |
Check Galmed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galmed Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 95.4 K, Interest Expense of 16.4 K or Selling General Administrative of 4.3 M, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or PTB Ratio of 0.17. Galmed financial statements analysis is a perfect complement when working with Galmed Pharmaceuticals Valuation or Volatility modules.
Galmed | Net Receivables | Build AI portfolio with Galmed Stock |
Analyzing Galmed Pharmaceuticals's Net Receivables over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Receivables has evolved provides context for assessing Galmed Pharmaceuticals's current valuation and future prospects.
Latest Galmed Pharmaceuticals' Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Galmed Pharmaceuticals over the last few years. It is Galmed Pharmaceuticals' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Galmed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Galmed Net Receivables Regression Statistics
| Arithmetic Mean | 114,398 | |
| Geometric Mean | 70,680 | |
| Coefficient Of Variation | 77.02 | |
| Mean Deviation | 72,892 | |
| Median | 109,000 | |
| Standard Deviation | 88,104 | |
| Sample Variance | 7.8B | |
| Range | 274K | |
| R-Value | 0.61 | |
| Mean Square Error | 5.2B | |
| R-Squared | 0.37 | |
| Significance | 0.01 | |
| Slope | 10,619 | |
| Total Sum of Squares | 124.2B |
Galmed Net Receivables History
About Galmed Pharmaceuticals Financial Statements
Galmed Pharmaceuticals stakeholders use historical fundamental indicators, such as Galmed Pharmaceuticals' Net Receivables, to determine how well the company is positioned to perform in the future. Although Galmed Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Galmed Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Galmed Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Galmed Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 240.3 K | 131.4 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:Check out the analysis of Galmed Pharmaceuticals Correlation against competitors. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Will Biotechnology sector continue expanding? Could Galmed diversify its offerings? Factors like these will boost the valuation of Galmed Pharmaceuticals. Market participants price Galmed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Galmed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Galmed Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Galmed's balance sheet. Smart investors calculate Galmed Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Galmed Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.